ISTA Pharmaceuticals Reports Third Quarter 2009 Financi...(9% QD confirmatory clinical study and ar...)

Date:11/3/2009

9% QD confirmatory clinical study and are working diligently to file a supplemental New Drug Application (sNDA) in 2009. Our rich late-stage pipeline includes a new low-dose formulation of bromfenac for dry eye, which is expected to enter Phase 3 studies during the first half of 2010, and bepotastine nasal spray, both of which represent even larger market opportunities than ocular allergy. We are confident in our core products and in our ability to grow our business even further over the coming years as we launch new products."

                                   Net Revenue
                      (in millions, except percentage data)

                 Three Months Three Months       Nine Months Nine Months
                    Ended        Ended              Ended      Ended
                  September    September     %    September  September   %
                  30, 2009     30, 2008   Change  30, 2009   30, 2008  Change

    Xibrom         $21.4        $16.2       32%     $55.1      $41.6     32%
    Istalol          5.1          3.9       31%      13.0        9.5     37%
    Vitrase          1.4          1.5       -7%       4.0        3.7      8%
    Bepreve          1.2          0.0        -        1.2        0.0      -
    Total product   29.1         21.6       35%      73.3       54.8     34%
    Other            2.9          0.1        -        3.1        0.2      -
    Total          $32.0        $21.7       47%     $76.4      $55.0     39%

Third Quarter and Year to Date Operating Details

Net revenue for the three and nine months ended September 30, 2009 was $32.0 and $76.4 million, respectively, or an increase of 47% and 39%, respectively, over the same periods of 2008. Included in net revenue for the three and nine months in 2009 is $1.2 million associated with the launch of Bepreve and $2.9 million of previously deferred revenue associated with the termination of a supply agreement.

Gross margin for the
'/>"/>

SOURCE ISTA Pharmaceuticals, Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9
Related biology technology :

1. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
2. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
5. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
6. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
7. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
8. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
9. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
10. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
11. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs